Advertisement

Topics

Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG Company Profile

06:02 EST 11th December 2018 | BioPortfolio


News Articles [2326 Associated News Articles listed on BioPortfolio]

M&As this week: Novartis, Takeda, Dechra Pharmaceuticals

M&As this week: Novartis, Takeda, Dechra Pharmaceuticals Novartis has entered an agreement to acquire Endocyte for approximately $2.1bn. The transaction...Read More... The post M&As this week...

Priority Changes for Novartis Spell the End for Aveo Pharma Alliance

When Aveo Pharmaceuticals found itself floundering three years ago in the wake of the FDA’s rejection of its lead cancer drug, Novartis threw out a lifeline: a partnership on another Aveo drug that ...

Novartis International AG: Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals

Novartis International AG / Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals . Processed and transmitted by West Corporation. The issuer is solely responsible for the...

Novartis forge deal with Boston Pharmaceuticals in effort against AMR

Swiss multinational Novartis have entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates in an effort to boost Nova...

Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates that are part of the No...

Open resources at Novartis help drive innovation

“Back in Argentina, you never think of going for a real drug, but coming to Novartis completely changed what I thought was possible,” says Bernardo Bazet Lyonnet, a postdoctoral researcher who fir...

Boston Pharma acquires worldwide rights for three novel anti─infective programmes from Novartis

Novartis has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti─infective drug candidates that are part of the Novartis Infectious Dise...

Novartis licenses anti-infective candidates to Boston Pharmaceuticals

Novartis has signed a licensing and equity agreement with Boston Pharmaceuticals to develop three anti-infective programmes for the potential treatment...Read More... The post Novartis licenses anti-i...

PubMed Articles [145 Associated PubMed Articles listed on BioPortfolio]

NVP-BHG712: Effects of regioisomers on the affinity and selectivity towards the EPHrin family.

EPH receptors are transmembrane receptor tyrosine kinases. Their extracellular domains bind specifically to ephrin A/B ligands, and this binding modulates the intracellular kinase activity. EPHs are k...

Perceptions of Kenyan adults on access to medicines for non-communicable diseases: A qualitative study.

In Kenya, noncommunicable diseases (NCDs) account for 27% of all deaths. Adult Kenyans have an 18% chance of dying prematurely from cancers, diabetes, cardiovascular diseases or chronic respiratory di...

Life sciences licensing deals in the second quarter of 2018: updates and trends.

During the second quarter of 2018, Cortellis Competitive Intelligence registered 985 new deals (excluding mergers and acquisitions) with a total disclosed deal value of USD 19.5 billion as part of its...

Rescue of Fmr1 phenotypes with mGluR inhibitors: MRZ-8456 versus AFQ-056.

Metabotropic glutamate receptor 5 (mGluR) is a drug target for central nervous system disorders such as fragile X syndrome that involve excessive glutamate-induced excitation. We tested the efficacy o...

How Often Do Safety Signals Occur by Chance in First-in-Human Trials?

Clinicians working on first-in-human clinical studies need to be able to judge whether safety signals observed on an investigational drug were more likely to have occurred by chance or to have been ca...

Clinical Trials [317 Associated Clinical Trials listed on BioPortfolio]

Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative

Countries throughout the world are facing a growing non-communicable disease (NCD) burden. In developing countries, medicines to treat NCDs are often difficult to access or too expensive f...

Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed Condition

The purpose of this study is to compare the single-dose oral bioavailability of oxcarbazepine 300 mg/5mL oral suspension of OHM Laboratories, USA (a subsidiary of Ranbaxy Pharmaceuticals I...

Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5 mL Under Fasting Conditions

The study was conducted as an open label, balanced, randomized, two-treatment, two-period, two-sequence, single- dose, crossover bioavailability study comparing oxcarbazepine 300 mg/5mL or...

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subject (Aged 6 to 72 Months) Versus Control Vaccines

This study will evaluate the safety, tolerability and immunogenicity of one or two 0.25mL or 0.5mL intramuscular injections of influenza vaccine compared with control vaccine in subjects 6...

Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study

The primary objective of this observational, comparative safety study is to evaluate the safety of the Novartis Pandemic Influenza A (H1N1) vaccine in pregnant women and their off spring, ...

Companies [2415 Associated Companies listed on BioPortfolio]

Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG

Novartis Consumer Health

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innova...

Novartis AG

Novartis's name, derived from the Latin novae artes, means "new skills" and reflects Novartis's commitment to focus research and development to bring new healthcare products to the...

Novartis Vaccines and Diagnostics

Novartis Vaccines is a global leader in providing vaccines to protect against deadly meningococcal disease. Through industry-leading scientific expertise, the company is focused on extending critical ...

Idenix Pharmaceuticals

Idenix is pursuing a disciplined business strategy that seeks to capitalize upon the diverse expertise of the company’s management team. While Idenix is focused on bringing its late-stage product ca...

More Information about "Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG" on BioPortfolio

We have published hundreds of Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG news stories on BioPortfolio along with dozens of Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG Clinical Trials and PubMed Articles about Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG Companies in our database. You can also find out about relevant Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record